A newly published study in JAMA Health Forum found that new Medicare Part D price caps on out-of-pocket prescription drug costs will help new beneficiaries switching from commercial plans. The study found that the $2000 price cap in the provision, included in the Inflation Reduction Act, would save people switching from commercial plans to Part D.
According to Frank Diamond, “The retrospective, population-based cohort study compared claims from 37,324 Part D beneficiaries to 24,159 commercially insured individuals who filled prescriptions for ultra-expensive medications from 2013 through 2019. The data were analyzed in February.”
To read more, click here.
(Source: Fierce Healthcare, May 26th, 2023)